Literature DB >> 9428347

Cell cycle and proliferation markers in neuroepithelial tumors.

P Cavalla1, D Schiffer.   

Abstract

Cell proliferation is characteristic, though non specific, of tumors. The cell cycle is regarded as a clock with ordered activation of protein complexes triggering initiation and advancement through checkpoints. The cell cycle and its control mechanisms are briefly described herein focusing on neuroepithelial tumors. The assessment of cell proliferation in brain tumors is a very important tool in diagnosis and especially in prognosis. It can be performed by different methods: counting mitoses, calculating the labeling index (Ll) of [3H] Thymidine, BrdU, Ki-67, MIB.1, PCNA, cytometry and AgNORs. Each method has its advantages and disadvantages. The main obstacles to the usefulness of different Lls in establishing prognosis in individual cases are sampling error, heterogeneity of the proliferation potential of brains tumors and the wide overlapping of Ll ranges between classic and anaplatic variants. The principal findings are critically described and commented upon.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9428347

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  4 in total

1.  Progression of astrocytomas and meningiomas: an evaluation in vitro.

Authors:  L Maes; J P O Kalala; M Cornelissen; L de Ridder
Journal:  Cell Prolif       Date:  2007-02       Impact factor: 6.831

2.  Modulation of glioma cell migration and invasion using Cl(-) and K(+) ion channel blockers.

Authors:  L Soroceanu; T J Manning; H Sontheimer
Journal:  J Neurosci       Date:  1999-07-15       Impact factor: 6.167

3.  ASTROCYTOMAS AND PROGNOSIS-FROM MORPHOLOGY TO TUMOR BIOLOGY.

Authors:  Ritu Lakhtakia; Arti Trehan; Ramji Rai; S Mukherjee
Journal:  Med J Armed Forces India       Date:  2017-06-10

4.  Expression and clinical significance of the proliferation marker minichromosome maintenance protein 2 (Mcm2) in diffuse astrocytomas WHO grade II.

Authors:  Tove Lind-Landström; Rosilin K Varughese; Stein Sundstrøm; Sverre H Torp
Journal:  Diagn Pathol       Date:  2013-04-24       Impact factor: 2.644

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.